Lv51
840 积分 2024-07-09 加入
Target and tissue selectivity of PROTAC degraders
7天前
已完结
Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation
7天前
已完结
Targeted Protein Degradation by Proteolysis Targeting Chimeras
18天前
已完结
Protein Degradation with New Chemical Modalities
18天前
已完结
Targeted protein degradation: from mechanisms to clinic
21天前
已完结
Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis
1个月前
已完结
From development to clinical success: the journey of established and next-generation BTK inhibitors
1个月前
已完结
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy
1个月前
已完结
Small-molecule BTK inhibitors: From discovery to clinical application
1个月前
已完结
Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure–activity relationship
1个月前
已完结
皖公网安备34019202002308
